Leading the Way in Life Science Technologies

GEN Exclusives

More »

Nov. 1, Vol. 25, No. 19

    • Point of View

    • Feature Articles

      • A New Spin on Plasma Biomarker Discovery
      • Ready availability and easy collection of plasma, which contains a huge variety of protein classes, make it attractive for prospecting for protein biomarkers. However, plasma is also one of the most complex sources to work with. Sample-to-sample va ... more »
      • Challenges Remain for Antibody Products
      • Despite the fact that monoclonal antibody technology celebrates its 30th birthday this year, its movement into adulthood has not brought a serene and settled maturity. "Going forward is difficult," according to Richard Siegel, Ph.D., vp fo ... more »
      • Commercial Bioactivities in Western Canada
      • The biotechnology industry in Canada's two western provinces dates back at least 20 years. In British Columbia "it's been going strong for the last 15 years," says Karimah Es Sabar, executive director of BC Biotech (www.bcbiotech.c ... more »
      • Emerging Technologies for Ion Channels
      • Fifteen of the top-100 best-selling drugs target ion channels, and ion channel function is implicated in a large number of diseases as disparate as Alzheimer's, epilepsy, heart disease, neuromuscular disease, and even cancer. Ion channels also r ... more »
    • Legal Affairs

      • Patent Rights and Pharmaceutical Reimportation
      • The ability of inventors to secure limited monopolies on their technologies through patent protection partly fuels the progress of scientific discovery. This has led to the development of breakthrough drugs that have increased the quality and durati ... more »
    • Wall Street BioBeat

      • How to Improve Series B-Round Valuations
      • How can biotech entrepreneurs and venture capitalists best meet the challenges of a Series B financing? One answer, surprisingly often overlooked, is the creative use of drug development domain expertise that gets products into the clinic quickly an ... more »
    • Tutorials

      • Electronic Laboratory Notebook Systems
      • The breakdown of traditional R&D silos in biotechnology and pharmaceutical companies has accelerated the drug discovery and development process, but it has also led to an increased need for robust communications and data-sharing mechanisms. Pape ... more »
      • The Shrinking Biomanufacturing Facility
      • The biopharmaceutical industry has experienced tremendous growth over the last ten years as a result of genetic engineering. The global market for biopharmaceuticals, valued at $48 billion in 2004, has been growing at a healthy compounding rate of 2 ... more »

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »